VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
-19.25%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$585M
AUM Growth
+$585M
(-34%)
Cap. Flow
-$154M
Cap. Flow
% of AUM
-26.38%
Top 10 Holdings %
Top 10 Hldgs %
61.33%
Holding
425
New
84
Increased
84
Reduced
102
Closed
119
Top Buys
| 1 |
Energy Transfer Partners
ET
|
$43.7M |
| 2 |
Enterprise Products Partners
EPD
|
$7.86M |
| 3 |
Oneok
OKE
|
$7.26M |
| 4 |
PSXP
PHILLIPS 66 PARTNERS LP
PSXP
|
$2.37M |
| 5 |
AM
ANTERO MIDSTREAM PARTNERS LP
AM
|
$2.31M |
Top Sells
| 1 |
ETP
Energy Transfer Partners, L.P.
ETP
|
$77.3M |
| 2 |
Marathon Petroleum
MPC
|
$24.9M |
| 3 |
EEP
Enbridge Energy Partners
EEP
|
$23.6M |
| 4 |
Phillips 66
PSX
|
$14.9M |
| 5 |
Williams Companies
WMB
|
$14.7M |
Sector Composition
| 1 | Energy | 82.73% |
| 2 | Healthcare | 7.29% |
| 3 | Utilities | 2.06% |
| 4 | Financials | 0.12% |
| 5 | Technology | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
151
Assertio
ASRT
$78M
| $266K | 0.05% |
+18,419
| New | +$266K |
|
152
Iovance Biotherapeutics
IOVA
$800M
| $266K | 0.05% |
30,077
-6,043
| -17% | -$53.4K |
|
153
ProQR Therapeutics
PRQR
$256M
| $263K | 0.04% |
+16,682
| New | +$263K |
|
|
ALLK
154
DELISTED
Allakos
ALLK
| $262K | 0.04% |
+5,014
| New | +$262K |
|
|
DRNA
155
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $261K | 0.04% |
+24,457
| New | +$261K |
|
156
Arrowhead Research
ARWR
$3.84B
| $252K | 0.04% |
20,261
-19,285
| -49% | -$240K |
|
157
TG Therapeutics
TGTX
$5.03B
| $252K | 0.04% |
61,557
+27,134
| +79% | +$111K |
|
158
Wave Life Sciences
WVE
$1.27B
| $252K | 0.04% |
+5,986
| New | +$252K |
|
|
AMRS
159
DELISTED
Amyris Inc.
AMRS
| $251K | 0.04% |
+75,294
| New | +$251K |
|
160
Marker Therapeutics
MRKR
$11.2M
| $250K | 0.04% |
+4,496
| New | +$250K |
|
161
Viking Therapeutics
VKTX
$3.02B
| $247K | 0.04% |
32,311
-7,649
| -19% | -$58.5K |
|
|
DCPH
162
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $247K | 0.04% |
11,773
+355
| +3% | +$7.45K |
|
|
ITCI
163
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $246K | 0.04% |
21,613
-645
| -3% | -$7.34K |
|
164
Inovio Pharmaceuticals
INO
$144M
| $242K | 0.04% |
5,033
-3,634
| -42% | -$175K |
|
165
Novavax
NVAX
$1.2B
| $241K | 0.04% |
6,560
-8,046
| -55% | -$296K |
|
|
OPTN
166
DELISTED
OptiNose
OPTN
| $238K | 0.04% |
+2,555
| New | +$238K |
|
167
Cytokinetics
CYTK
$5.98B
| $237K | 0.04% |
37,487
-12,590
| -25% | -$79.6K |
|
168
Fate Therapeutics
FATE
$115M
| $235K | 0.04% |
18,340
-19,754
| -52% | -$253K |
|
|
APTX
169
DELISTED
Aptinyx Inc. Common Stock
APTX
| $230K | 0.04% |
+13,905
| New | +$230K |
|
|
TCDA
170
DELISTED
Tricida, Inc. Common Stock
TCDA
| $227K | 0.04% |
+9,633
| New | +$227K |
|
|
IMMU
171
DELISTED
Immunomedics Inc
IMMU
| $226K | 0.04% |
15,848
-3,818
| -19% | -$54.4K |
|
172
NRG Energy
NRG
$28.4B
| $224K | 0.04% |
5,650
| – | – |
|
|
LJPC
173
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $224K | 0.04% |
23,806
+8,545
| +56% | +$80.4K |
|
174
Geron
GERN
$893M
| $216K | 0.04% |
216,245
+94,899
| +78% | +$94.8K |
|
175
Akebia Therapeutics
AKBA
$827M
| $211K | 0.04% |
38,183
-3,854
| -9% | -$21.3K |
|